Innovative therapeutic cancer vaccine PDC∗lung01 with or without anti-PD-1: an open-label, dose-escalation phase I/II study in non-small-cell lung cancer. - Vansteenkiste J; Demedts I; Cuppens K; Pons-Tostivint E; Wauters E; Borm FJ; Sibille A; Colinet B; Pérol M; Theelen WSME; Biesma B; Van De Kerkhove C; et al. (ESMO open, 2025)